Bristol Myers announces ‘positive’ results from Phase 3 Sotyktu trials

Bristol Myers (BMY) Squibb announced results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving ACR20 response after 16 weeks of treatment compared with placebo. Additionally, the POETYK PsA-1 and POETYK PsA-2 trials met important secondary endpoints across PsA disease activity at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials.